Publication & Citation Trends
Publications
0 total
Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma OA
Cited by 5
Semantic Scholar
Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trials.
Cited by 6
Semantic Scholar
POSTER: MM-304 Efficacy Outcomes and Characteristics of Patients With Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity After Treatment With Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1 OA
Cited by 0
Semantic Scholar
MM-309 CARTITUDE-1 Final Results: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma
Cited by 1
Semantic Scholar
702 Phase 1 study of DLL3-directed chimeric antigen receptor T-cells in subjects with extensive stage small cell lung cancer OA
Cited by 5
Semantic Scholar
MM-304 Efficacy Outcomes and Characteristics of Patients With Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity After Treatment With Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1
Cited by 0
Semantic Scholar
P28 EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER EXPOSURE TO NON-CELLULAR ANTI-B-CELL MATURATION ANTIGEN (BCMA) IMMUNOTHERAPY OA
Cited by 0
Semantic Scholar
Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma. OA
Cited by 13
Semantic Scholar
Research Topics
CAR-T cell therapy research
(89)
Multiple Myeloma Research and Treatments
(64)
Biosimilars and Bioanalytical Methods
(29)
Protein Degradation and Inhibitors
(25)
Lymphoma Diagnosis and Treatment
(14)
Affiliations
Université Paris-Sud
Novartis (Switzerland)
The University of Texas MD Anderson Cancer Center
VA Boston Healthcare System
Sanofi (France)